Akkermansia for Gut Barrier Integrity

The mechanistic case for Akkermansia and gut barrier function is strong, but human outcome data comes from a single small exploratory trial.

A. muciniphila lives in and renews the intestinal mucus layer. Its surface protein Amuc_1100 signals through TLR2 to tighten epithelial junctions, and mucin turnover cross-feeds short-chain-fatty-acid producers that fuel colonocytes.

The human evidence rests on a 2019 exploratory randomized, double-blind, placebo-controlled trial in 32 insulin-resistant overweight adults (Depommier et al., Nature Medicine). Three months of pasteurized A. muciniphila improved insulin sensitivity and lowered markers of hepatic stress, alongside a small reduction in body weight. Barrier-relevant endpoints such as plasma LPS moved in the right direction but the trial was underpowered for them. Animal work is far more emphatic: supplementation restores mucus thickness, reduces endotoxaemia and reverses diet-induced barrier loss in mice. Honest negative: no trial has yet measured intestinal permeability directly as a primary endpoint in humans, and the pasteurized form beating the live form remains counterintuitive enough to warrant replication.

People with low fibre intake are unlikely to see much - the organism needs mucin and dietary substrate to matter.